Trials / Completed
CompletedNCT00127829
Study Evaluating Gefitinib (IRESSA®) in Subjects With Solid Malignancies That Are Locally Advanced, Recurrent or Metastatic
A Phase I, Open-Label, Dose Escalation Study Evaluating High-Dose Gefitinib (IRESSA®) on Weekly and Twice Weekly Schedules in Subjects With Solid Malignancies That Are Locally Advanced, Recurrent or Metastatic
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 66 (estimated)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will determine the safety profile and maximum tolerated dose (MTD) of orally administered gefitinib on a weekly and twice weekly schedule.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Gefitinib | Oral tablet |
Timeline
- Start date
- 2005-07-01
- Completion
- 2008-01-01
- First posted
- 2005-08-09
- Last updated
- 2009-04-23
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00127829. Inclusion in this directory is not an endorsement.